BLAINTRAMUSCULARINJECTION, SUSPENSION1 Generic Approved
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
Spikevax (covid-19 vaccine, mrna) by Moderna. Approved for immunocompromised patients. First approved in 2025.
Drug data last refreshed 20h ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Clinical Trials (3)
Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE
Started Mar 2023
4,207 enrolled
SARS-CoV-2
Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy
Started Mar 2023
1,192 enrolled
Maternal OutcomesInfant OutcomesPregnancy
A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)
Started Apr 2022
1,500 enrolled
Myocarditis
Worked on Spikevax at Moderna? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.